Literature DB >> 15271837

Challenges for the National Institute for Clinical Excellence.

Alan Maynard1, Karen Bloor, Nick Freemantle.   

Abstract

Keywords:  Health Care and Public Health; National Institute for Clinical Excellence (Great Britain)

Mesh：

Year:  2004        PMID： 15271837      PMCID： PMC487743          DOI： 10.1136/bmj.329.7459.227

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  6 in total

1.  A fair innings for NICE?

Authors:  Nick Freemantle; Karen Bloor; Joanne Eastaugh
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

2.  Efficacy, safety, and cost of new anticancer drugs.

Authors:  Silvio Garattini; Vittorio Bertele
Journal:  BMJ       Date:  2002-08-03

3.  FDA chief wants other rich countries to share drug development costs.

Authors:  Janice Hopkins Tanne
Journal:  BMJ       Date:  2003-10-11

4.  National Institute for Clinical Excellence and its value judgments.

Authors:  Michael D Rawlins; Anthony J Culyer
Journal:  BMJ       Date:  2004-07-24

5.  Regulating the pharmaceutical industry.

Authors:  A Maynard; K Bloor
Journal:  BMJ       Date:  1997-07-26

Review 6.  Intergenerational equity: an exploration of the 'fair innings' argument.

Authors:  A Williams
Journal:  Health Econ       Date:  1997 Mar-Apr       Impact factor: 3.046
  6 in total
  13 in total

1.  NICE and its value judgments: favourable appraisal amounts to compulsory purchase order.

Authors:  Jammi N Rao
Journal:  BMJ       Date:  2004-09-25

2.  Is NICE delivering the goods?

Authors:  Nick Freemantle
Journal:  BMJ       Date:  2004-10-30

Review 3.  Prognosis without treatment as a modifier in health economic assessments.

Authors:  Ross Camidge; Andrew Walker; James J Oliver; Fiona Nussey; Simon Maxwell; Duncan Jodrell; David J Webb
Journal:  BMJ       Date:  2005-06-11

Review 4.  Seven years of feast, seven years of famine: boom to bust in the NHS?

Authors:  Alan Maynard; Andrew Street
Journal:  BMJ       Date:  2006-04-15

Review 5.  Information created to evade reality (ICER): things we should not look to for answers.

Authors:  Stephen Birch; Amiram Gafni
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 6.  Economic evaluation and decision making in the UK.

Authors:  Martin J Buxton
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

7.  To fund or not to fund: development of a decision-making framework for the coverage of new health technologies.

Authors:  Tania Stafinski; Devidas Menon; Christopher McCabe; Donald J Philippon
Journal:  Pharmacoeconomics       Date:  2011-09       Impact factor: 4.981

Review 8.  Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies.

Authors:  Brian Godman; Alan Haycox; Ulrich Schwabe; Roberta Joppi; Silvio Garattini
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

9.  NICE guidelines on anti-tumor necrosis factor therapy for RA.

Authors:  David L Scott; Sophia Steer
Journal:  Nat Clin Pract Rheumatol       Date:  2008-12-02

Review 10.  Societal values in the allocation of healthcare resources: is it all about the health gain?

Authors:  Tania Stafinski; Devidas Menon; Deborah Marshall; Timothy Caulfield
Journal:  Patient       Date:  2011       Impact factor: 3.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.